ReviewDiscover oncology2026
The crucial role of m6A methylation modification in nasopharyngeal carcinoma.
Review in Discover oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Nasopharyngeal carcinoma (NPC) is an epithelial malignancy originating from the nasopharyngeal mucosa and represents one of the most prevalent malignant tumors globally. RNA modifications function as a key epigenetic regulatory mechanism, governing post-transcriptional gene regulation. Among these, N6-methyladenosine (m6A) is the most abundant internal modification in eukaryotic mRNA and plays a pivotal role in regulating RNA transcription, splicing, stability, and translation. Extensive research has demonstrated that m6A modification regulates the expression of numerous oncogenes and tumor suppressor genes and is closely associated with cancer initiation and progression. Notably, regulators of m6A methylation exhibit aberrant expression in NPC tissues, and their dysregulation is closely linked to tumor development and therapeutic resistance. This evidence suggests their potential as molecular targets for NPC diagnosis and treatment. This review examines the pivotal role of m6A in NPC, encompassing its influence on cell proliferation, migration, invasion, and resistance to radiotherapy and chemotherapy. Furthermore, it explores recent advances in the application of m6A for NPC diagnosis and molecularly targeted therapy, and summarises current techniques for detecting m6A modifications.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.